Edition:
United States

Medtronic PLC (MDT.N)

MDT.N on New York Stock Exchange

80.16USD
20 Sep 2017
Change (% chg)

$-1.03 (-1.27%)
Prev Close
$81.19
Open
$81.19
Day's High
$81.49
Day's Low
$79.36
Volume
1,533,247
Avg. Vol
1,436,022
52-wk High
$89.71
52-wk Low
$69.35

Latest Key Developments (Source: Significant Developments)

Medtronic Canada receives Health Canada licence for MRI conditional cardiac resynchronization therapy defibrillators
Wednesday, 26 Jul 2017 09:30am EDT 

July 26 (Reuters) - Medtronic Canada::Received Health Canada licence for, is launching MRI conditional cardiac resynchronization therapy defibrillators for heart failure.  Full Article

Medtronic plc says ‍in June of 2017 company experienced a disruption in its information technology systems - SEC filing​
Tuesday, 18 Jul 2017 06:55am EDT 

July 18 (Reuters) - Medtronic Plc :Medtronic plc - for fiscal year 2018, company reiterates its expectation that its constant currency revenue growth will be in range of 4 to 5 percent.Medtronic - ‍in Form 10-K filed with SEC on June 27, co reported that its information technology systems had been fully restored​.Medtronic - for FY 2018, company reiterates adjusted diluted EPS growth will be in range of 9 to 10 percent on a constant currency basis.Medtronic says ‍company did not believe its fiscal year 2018 results of operations or financial condition would be materially affected by incident​.Medtronic - ‍company expects growth at lower end of range in Q1​.Medtronic - ‍reiterates guidance range for adjusted earnings per share growth for fiscal Q1 of 2018 at upper end of high-single digit range on a constant currency basis​.FY2018 earnings per share view $4.95, revenue view $31.12 billion -- Thomson Reuters I/B/E/S.Medtronic - ‍reiterates its prior guidance range for both fiscal Q1 and full year revenue growth on a constant currency basis in range of 4 to 5 percent​.Medtronic - ‍fiscal year 2018 outlook does not include impact of divestiture of a portion of its patient monitoring and recovery division​.Medtronic - ‍given its disruption, strong new product demand in Diabetes Group versus temporarily limited supply of sensors, sees revenue growth at lower end of Q1​ range.FY2018 revenue view $31.12 billion -- Thomson Reuters I/B/E/S.  Full Article

Medtronic Plc ‍announces first enrollments in STOP AF First clinical trial​
Tuesday, 11 Jul 2017 10:00am EDT 

July 11 (Reuters) - Medtronic Plc ::Clinical trial to evaluate Medtronic Cryoablation as first-line treatment for patients with symptomatic paroxysmal atrial fibrillation.Medtronic Plc- ‍announced first enrollments in STOP AF First clinical trial​.  Full Article

Medtronic announces expanded FDA approval of self-expanding Corevalve Evolut TAVR platform​
Monday, 10 Jul 2017 11:35am EDT 

July 10 (Reuters) - Medtronic Plc : :Medtronic expands TAVR access to more patients with symptomatic, severe aortic stenosis upon intermediate risk FDA approval.Medtronic Plc- ‍expanded U.S. FDA approval of self-expanding Corevalve Evolut Transcatheter Aortic Valve Replacement platform​.Medtronic - ‍Expanded FDA approval to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery​.  Full Article

Medtronic announces agreement with Aetna for diabetes patients
Monday, 26 Jun 2017 09:00am EDT 

June 26 (Reuters) - Medtronic Plc ::Medtronic announces outcomes-based agreement with Aetna for Type 1 and Type 2 diabetes patients.Medtronic - ‍agreement to measure health outcomes for patients that choose to transition to pump therapy using Medtronic insulin pump featuring Smartguard technology​.Medtronic ‍announces new outcomes-based agreement with Aetna for Type 1 and Type 2 diabetes patients currently on multiple daily insulin injections.  Full Article

Medtronic announces 7 pct increase in cash dividend
Friday, 23 Jun 2017 06:45am EDT 

June 23 (Reuters) - Medtronic Plc ::Medtronic announces 7 percent increase in cash dividend.Increases quarterly cash dividend by 7 percent to $0.46 per share.Medtronic Plc - board authorized expenditure of up to $5.0 billion for new share repurchases.Medtronic Plc says authorization replaces previous 2015 repurchase authorization to redeem up to an aggregate number of ordinary shares.Medtronic Plc - is no specific time-period associated with repurchase authorization.  Full Article

Medtronic initiates U.S. launch of world's first hybrid closed loop system for type 1 diabetes​
Wednesday, 7 Jun 2017 09:11am EDT 

June 7 (Reuters) - Medtronic Plc :Medtronic Plc - ‍initiates u.s. Launch of world's first hybrid closed loop system for type 1 diabetes​.  Full Article

Medtronic gets Health Canada licence for SureTune3 software
Tuesday, 6 Jun 2017 10:00am EDT 

June 6 (Reuters) - Medtronic Plc :Medtronic Plc <<>> says it has received a health canada licence for suretune 3 software for deep brain stimulation.  Full Article

QT Vascular updates on potential transaction with Medtronic
Sunday, 21 May 2017 08:07pm EDT 

May 22 (Reuters) - QT Vascular Ltd :Negotiations in relation to possible transaction(s) involving company's coronary product(s).Possible transaction(s) does not conflict with Medtronic transaction and will be in addition to it.Refers to potential transaction with Medtronic involving disposal of its non-drug coated peripheral asset.  Full Article

Medtronic receives FDA approval for MR-conditional quadripolar cardiac resynchronization therapy-pacemakers
Wednesday, 10 May 2017 11:15am EDT 

May 10 (Reuters) - Medtronic plc ::Medtronic first to receive FDA approval for MR-conditional quadripolar cardiac resynchronization therapy-pacemakers.The quadripolar cardiac resynchronization therapy-pacemakers are expected to be available commercially in United States in early summer 2017.  Full Article

BRIEF-Medtronic announces FDA approval, U.S. launch of spinal cord stimulator

* Medtronic announces FDA approval and U.S. launch of next generation spinal cord stimulator for chronic pain management Source text for Eikon: Further company coverage: